세계의 치료 저항성 우울증(TRD) 시장 예측 : 치료 모달리티별, 유통 채널별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Treatment-Resistant Depression Market is accounted for $2.1 billion in 2024 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 11.8% during the forecast period. Treatment-resistant depression (TRD) is a form of major depressive disorder that does not respond adequately to at least two different antidepressant treatments of sufficient dose and duration. It affects approximately 30% of people with depression. TRD is characterized by persistent depressive symptoms despite standard interventions, often requiring alternative strategies like medication combinations, psychotherapy, brain stimulation techniques, or novel therapies. It poses significant challenges for patients and clinicians, leading to increased functional impairment, higher healthcare costs, and a greater risk of suicidal behavior compared to non-resistant depression.

According to data from a study published in the American Journal of Psychiatry in May 2024, the estimated 12-month prevalence of medication-treated major depressive disorder (MDD) in the United States was 8.9 million adults.

Market Dynamics:

Driver:

Increasing prevalence of depression

The rising prevalence of depression globally is a key driver for the treatment-resistant depression market. According to the World Health Organization, over 300 million people suffer from depression worldwide. As the number of depression cases increases, so does the subset of patients with treatment-resistant depression. This growing patient pool creates a larger market for advanced therapies and drives research and development efforts to find more effective treatments for this challenging condition.

Restraint:

High cost of treatment

The high cost of treatment for treatment-resistant depression poses a significant restraint on market growth. Novel therapies like ketamine infusions, transcranial magnetic stimulation, and esketamine nasal sprays are expensive and often not covered by insurance. For example, a course of ketamine infusions can cost thousands of dollars. These high out-of-pocket costs limit access to treatment for many patients and hinder widespread adoption of newer therapies, potentially slowing market expansion.

Opportunity:

Pipeline of novel therapies

The robust pipeline of novel therapies for treatment-resistant depression presents a significant market opportunity. Several promising compounds are in late-stage clinical trials, including psychedelics like psilocybin, new glutamatergic agents, and innovative drug combinations. For instance, COMP360 (psilocybin therapy) has shown positive results in phase 2 trials. The potential approval of these novel treatments could expand treatment options, improve outcomes, and drive market growth by addressing the unmet needs of treatment-resistant patients.

Threat:

Stringent regulatory environment

Regulatory agencies like the FDA require extensive clinical trial data and safety profiles for new drug approvals, especially for novel mechanisms of action. This rigorous process can lead to delays, increased development costs, and potential failures in bringing new treatments to market. The regulatory hurdles may discourage investment in innovative therapies and slow the pace of new treatment options becoming available.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the treatment-resistant depression market. Lockdowns and social isolation have led to increased rates of depression and anxiety, potentially expanding the patient pool. Simultaneously, disruptions in healthcare access and clinical trials have affected treatment delivery and research progress. However, the pandemic has also accelerated the adoption of telemedicine and digital mental health solutions, opening new avenues for treatment delivery and market growth.

The retail pharmacies segment is expected to be the largest during the forecast period

The retail pharmacies segment is projected to dominate the treatment-resistant depression market during the forecast period. Retail pharmacies offer convenient access to prescription medications for patients with treatment-resistant depression. They play a crucial role in medication dispensing, patient education, and adherence support. The increasing availability of novel antidepressants and adjunctive therapies through retail channels contributes to this segment's growth. Additionally, the trend towards outpatient management of depression and the rising number of retail pharmacy chains globally further drive the expansion of this segment.

The neurostimulation segment is expected to have the highest CAGR during the forecast period

The neurostimulation segment is anticipated to experience the highest CAGR in the treatment-resistant depression market. This growth is driven by the increasing adoption of non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). These methods offer alternative treatment options for patients who have not responded to traditional pharmacotherapy. The growing body of evidence supporting the efficacy of neurostimulation techniques, coupled with technological advancements improving their safety and tolerability, contributes to the rapid expansion of this segment.

Region with largest share:

During the forecast period, the North American region is expected to dominate the treatment-resistant depression market. North America's dominance can be attributed to factors such as the high prevalence of depression, well-established healthcare infrastructure, and early adoption of novel therapies. The region also benefits from significant research and development investments, the presence of key market players, and favorable reimbursement policies. Additionally, increased awareness about mental health and growing acceptance of innovative treatments contribute to North America's leading position in the market.

Region with highest CAGR:

During the forecast period, the Asia Pacific region is expected to witness rapid growth in the treatment-resistant depression market. This growth is driven by factors such as increasing awareness about mental health, improving healthcare infrastructure, and rising healthcare expenditure. The large population base and growing prevalence of depression in countries like China and India present significant market opportunities. Additionally, the expansion of pharmaceutical companies into the region and increasing government initiatives to address mental health issues contribute to the rapid market growth in Asia Pacific.

Key players in the market

Some of the key players in Treatment-Resistant Depression market include AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb Company, Forest Laboratories, Vistagen Therapeutics, Inc., Novartis, AbbVie Inc., H. Lundbeck A/S, Sandoz International GmbH, Otsuka Pharmaceutical Co., Ltd., Par Pharmaceutical, Mylan N.V., Aurobindo Pharma, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In August 2024, AbbVie announced that it has completed its acquisition of Cerevel Therapeutics. With the completion of the acquisition, Cerevel is now part of AbbVie. "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael, chief executive officer, AbbVie.

In July 2024, Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO(R) (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

In December 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR(R) (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.

Treatment Modalities Covered:

• Pharmacotherapy
• Psychotherapy
• Neurostimulation
• Combination Therapies

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Telemedicine Platforms

End Users Covered:

• Hospitals
• Specialty Clinics
• Outpatient Clinics
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Treatment-Resistant Depression Market, By Treatment Modality

• 5.1 Introduction
• 5.2 Pharmacotherapy
  • 5.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
  • 5.2.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • 5.2.3 Tricyclic Antidepressants (TCAs)
  • 5.2.4 Monoamine Oxidase Inhibitors (MAOIs)
  • 5.2.5 Antipsychotics
  • 5.2.6 Mood Stabilizers
  • 5.2.7 Ketamine and Esketamine
  • 5.2.8 Other Pharmacotherapies
• 5.3 Psychotherapy
  • 5.3.1 Cognitive Behavioral Therapy (CBT)
  • 5.3.2 Interpersonal Therapy (IPT)
  • 5.3.3 Psychodynamic Therapy
  • 5.3.4 Other Psychotherapies
• 5.4 Neurostimulation
  • 5.4.1 Transcranial Magnetic Stimulation (TMS)
  • 5.4.2 Deep Brain Stimulation (DBS)
  • 5.4.3 Vagus Nerve Stimulation (VNS)
  • 5.4.4 Electroconvulsive Therapy (ECT)
  • 5.4.5 Other Neurostimulation Therapies
• 5.5 Combination Therapies

6 Global Treatment-Resistant Depression Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Online Pharmacies
• 6.5 Telemedicine Platforms

7 Global Treatment-Resistant Depression Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Specialty Clinics
• 7.4 Outpatient Clinics
• 7.5 Research Institutes
• 7.6 Other End Users

8 Global Treatment-Resistant Depression Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AstraZeneca
• 10.2 Pfizer Inc.
• 10.3 GlaxoSmithKline plc
• 10.4 Eli Lilly and Company
• 10.5 Johnson & Johnson
• 10.6 Bristol-Myers Squibb Company
• 10.7 Forest Laboratories
• 10.8 Vistagen Therapeutics, Inc.
• 10.9 Novartis
• 10.10 AbbVie Inc.
• 10.11 H. Lundbeck A/S
• 10.12 Sandoz International GmbH
• 10.13 Otsuka Pharmaceutical Co., Ltd.
• 10.14 Par Pharmaceutical
• 10.15 Mylan N.V.
• 10.16 Aurobindo Pharma
• 10.17 Teva Pharmaceutical Industries Ltd.